Back to Newsroom

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

TÜBINGEN, Germany, July 1, 2014 – CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

Click here to read more